Evidence map›Paper›PMID 42374136›Full record

ArticleCommunications chemistry2026

Assessing crystallisation behaviour in molecular crystals through particle rugosities.

Marta Brocca, Dominic Evans, Helen Blade, Sten O Nilsson Lill, Aurora J Cruz-Cabeza

Abstract read
In one paragraph

Article in Communications chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marta BroccaDepartment of Chemistry, University of Durham, Durham, UK.ORCID http://orcid.org/0009-0009-5089-3621
Dominic EvansDepartment of Chemistry, University of Durham, Durham, UK.
Helen BladeGlobal Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca Macclesfield, Cheshire, UK.
Sten O Nilsson LillPredictive Science, Digital & Automation, Pharmaceutical Sciences, R&D, AstraZeneca Gothenburg, Mölndal, Sweden.
Aurora J Cruz-CabezaDepartment of Chemistry, University of Durham, Durham, UK. aurora.j.cruz-cabeza@durham.ac.uk.ORCID http://orcid.org/0000-0002-0957-4823

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surface properties of molecular crystals play a central role in determining their nucleation, growth, and overall crystallisation behaviour. In particular, surface rugosity has been suggested as a meaningful descriptor of how readily a crystal may nucleate and grow, but the existing rugosity metrics have been limited by incomplete descriptions of surface topology. In this study, we present a new workflow for the computation of surface descriptors across crystal facets. Here the surface rugosity description for each facet is based on the Surface Area Ratio (SAR) definition proposed in the Cambridge Structural Database (CSD) tools. Given a crystal structure, our algorithm computes an average overall particle rugosity with three offset selection criteria that account for different crystallisation conditions. We then calculate particle rugosities and analyse data for a range of systems, including: polymorphic families, datasets from the CSD, and crystal structure prediction (CSP) landscapes. Our analysis shows that, in most cases, polymorphs with lower rugosities tend to nucleate and grow more readily, suggesting that this metric can distinguish experimentally accessible forms from more elusive ones. These findings demonstrate that particle rugosities can serve as a complementary tool for predicting and classifying the experimental feasibility of polymorphs generated computationally.

Identifiers

PMID42374136
PMCPMC13346652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.